About
About us
Business Model
Team
Scientific Advisors
Sevuparin
About Sevuparin
Actions of sevuparin
Further reading
Research & Development
Pipeline
About Sepsis
About anemia and CKD
About severe malaria
Sevuparin and sepsis
Sevuparin and hepcidin
Sevuparin and malaria
Investors
IPO 2021/ TO1 2022
Issues 2023
Share
News
Financial Reports
Presentations
Calendar
Corporate Governance
Analyst Coverage
News
Contact
EN
SV
All Press Releases
ALL PRESS RELEASES 2019
May 31, 2019
Notice Of Annual General Meeting In Modus Therapeutics Holding AB (Publ) In Swedish
>
May 13, 2019
Modus Therapeutics Announces The Results Of Its Global, Randomized, Placebo-Controlled Phase 2 Clinical Trial Evaluating Sevuparin For The Management Of Acute Vaso-Occlusive Crisis (VOC) In Patients With Sickle Cell Disease (SCD)
>
Mar 11, 2019
Modus Therapeutics Strengthens Management Team With Appointment Of Mats Blom, MBA As CFO
>
Feb 22, 2019
First Cohort Dosed In U.S. Phase 1 Study Of Subcutaneously Administered Sevuparin
>
Jan 29, 2019
Modus Therapeutics Strengthens Board With Two Key Appointments
>
